Strategies to minimize readmission rates following major urologic surgery
- PMID: 28588648
- PMCID: PMC5444623
- DOI: 10.1177/1756287217701699
Strategies to minimize readmission rates following major urologic surgery
Abstract
Readmissions after major surgical procedures are prevalent across multiple disciplines. Specifically, in urology, with incorporation of early discharge and recovery pathways, readmissions are emerging as an important problem and effecting an epidemic proportion of urology patients. As expected, readmissions have garnered the attention of major healthcare payers in the United States who see readmissions as easy targets because of the association with astronomical costs. More importantly, readmissions have a significant negative impact on patient sense of wellbeing, and places economic and other hardships on the doors of our patients and their families. Here, we explore the reasons patients are readmitted, using radical cystectomy as a case study, and means to decrease the incidence of readmissions. Since time to readmission for most major urologic oncology surgeries is within the first 2 weeks after discharge, this time frame is critical for efforts to improve symptom identification and reduce the total number and severity of readmissions. Readmission reduction to zero is unlikely for any major surgery, but with effective coordinated strategies, we must strive to reduce the rates as much as possible, as a means to improve the care continuum for our patients.
Keywords: cystectomy; delivery of health care; health planning; patient readmission; urologic surgical procedures; urology.
Conflict of interest statement
Conflict of interest statement: Janet Baack Kukreja: No conflicts of interest. Ashish Kamat-Research Support: FKD Indus-tries, Photocure, Merck, and Heat Biologics. Consultant/Speaker: Cepheid, Photocure, Telesta Therapeutics, Sanofi, Merck, Abbott Molecular, Theralase, Heat Biologics, Spectrum Pharma-ceuticals, Oncogenix. Patents: Patent Pending - Cytokine assay for BCG (CYPRIT) - The University of Texas MD Anderson Cancer Center.
Figures
References
-
- Stitzenberg KB, Chang Y, Smith AB, et al. Impact of location of readmission on outcomes after major cancer surgery. Ann Surg Oncol 2017; 24: 319–329. - PubMed
-
- Downs TM. Reducing readmissions and mortality after radical cystectomy. J Urol 2015; 193: 1461–1462. - PubMed
-
- Gandaglia G, Sammon JD, Chang SL, et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol 2014; 32: 1419–1426. - PubMed
-
- Schmid M, Chiang HA, Sood A, et al. Causes of hospital readmissions after urologic cancer surgery. Urol Oncol Semin Orig Investig 2016; 34: 236 e231–e211. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials